Figure 13. K‐M analysis of post‐progression survival (PPS) using a Mito‐Signature in ER(+) and all breast cancer patients, independently of treatment. Patients with high‐expression levels of the Mito‐Signature showed near 1.5‐fold reductions in post‐progression survival. Left, ER(+) (N = 313 patients; p = 0.01). Right, all breast cancer (N = 414 patients; p = 0.0055).